• GH Research (GHRS) shares are trading up 8.1% today at $28.75, following reports of Eli Lilly's advanced negotiations to acquire psychedelic-medicine developer AtaiBeckley.
  • The potential acquisition, which was reported on the evening of July 15, sent shockwaves through the psychedelic therapeutics sector and raised prospects for further consolidation.
  • RBC Capital Markets analyst Brian Abrahams identified GH Research as the "most direct and compelling read-through" to the acquisition, citing the similar mechanism of its lead asset, GH001, to AtaiBeckley's BPL-003.